See more : GHL Systems Berhad (0021.KL) Income Statement Analysis – Financial Results
Complete financial analysis of Alpa Laboratories Limited (ALPA.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alpa Laboratories Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Porsche Automobil Holding SE (PAH3.DE) Income Statement Analysis – Financial Results
- Nihon M&A Center Holdings Inc. (2127.T) Income Statement Analysis – Financial Results
- Applied BioCode Corporation (6598.TW) Income Statement Analysis – Financial Results
- John Wood Group PLC (WG.L) Income Statement Analysis – Financial Results
- Baselode Energy Corp. (BSENF) Income Statement Analysis – Financial Results
Alpa Laboratories Limited (ALPA.BO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.alpalabs.in
About Alpa Laboratories Limited
Alpa Laboratories Limited manufactures and sells pharmaceutical finished dosage forms in India. The company offers ethical, generic, and over the counter products in various finished dosage forms, including injections, tablets, capsules, eye and ear drops, ointments, creams, and gels for human and veterinary use. It also provides drugs in various categories, such as anti-infectives comprising antibacterial, antibiotics, antifungals, antiprotozoals, and antivirals; analgesics; anti-inflammatory drugs; cough and cold drugs; cardiovascular drugs; anti-diabetics; nutritional supplements; psychotropic drugs; and skin care preparations, as well as ear and eye care preparations. It sells its products through distributors, retail chemists, retail pharmacy stores, and hospitals. The company also exports its products to South and Central America, Africa, and Asia, Russia, Ukraine, Kazakhstan, and internationally. Alpa Laboratories Limited was founded in 1967 and is based in Indore, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.09B | 924.10M | 1.11B | 964.14M | 848.70M | 764.22M | 618.98M | 625.42M | 535.90M | 573.94M | 567.08M | 561.10M | 551.30M | 828.67M | 934.37M | 1.22B |
| Cost of Revenue | 746.75M | 614.97M | 760.87M | 647.56M | 552.65M | 530.89M | 398.11M | 396.22M | 307.19M | 400.10M | 366.46M | 403.19M | 429.78M | 730.80M | 843.84M | 1.13B |
| Gross Profit | 340.64M | 309.13M | 344.26M | 316.58M | 296.05M | 233.33M | 220.87M | 229.21M | 228.71M | 173.84M | 200.63M | 157.90M | 121.52M | 97.87M | 90.53M | 89.75M |
| Gross Profit Ratio | 31.33% | 33.45% | 31.15% | 32.84% | 34.88% | 30.53% | 35.68% | 36.65% | 42.68% | 30.29% | 35.38% | 28.14% | 22.04% | 11.81% | 9.69% | 7.38% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 133.62M | 10.77M | 17.23M | 22.03M | 20.78M | 18.82M | 10.24M | 14.30M | 11.06M | 85.22M | 6.19M | 6.05M | 0.00 | 45.32M | 46.61M | 42.65M |
| Selling & Marketing | 22.53M | 51.61M | 57.93M | 44.88M | 53.43M | 50.04M | 41.19M | 30.41M | 10.42M | 2.85M | 28.50M | 19.20M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 156.15M | 62.38M | 75.16M | 66.91M | 74.20M | 68.86M | 51.44M | 44.70M | 21.48M | 88.08M | 134.67M | 105.02M | 0.00 | 45.32M | 46.61M | 42.65M |
| Other Expenses | 0.00 | 28.82M | 1.48M | 516.00K | 1.06M | 467.00K | 416.00K | 134.00K | 747.00K | 1.08M | 150.00K | 224.00K | 5.00K | 186.41K | 0.00 | 0.00 |
| Operating Expenses | 156.15M | 235.52M | 248.85M | 219.42M | 250.81M | 237.88M | 199.61M | 172.63M | 145.52M | 192.14M | 234.46M | 173.77M | 105.85M | 91.55M | 70.16M | 78.74M |
| Cost & Expenses | 902.89M | 850.49M | 1.01B | 866.97M | 803.46M | 768.77M | 597.72M | 568.85M | 452.71M | 592.24M | 600.91M | 576.96M | 535.63M | 822.35M | 914.00M | 1.21B |
| Interest Income | 23.18M | 10.45M | 14.58M | 6.54M | 5.34M | 29.06M | 31.77M | 37.62M | 40.51M | 25.58M | 585.00K | 423.00K | 262.00K | 326.12K | 0.00 | 22.66M |
| Interest Expense | 3.59M | 825.00K | 1.07M | 261.00K | 951.00K | 4.77M | 7.81M | 16.32M | 12.75M | 15.01M | 20.93M | 19.45M | 12.42M | 2.01M | 0.00 | 19.55M |
| Depreciation & Amortization | 19.55M | 13.29M | 16.57M | 12.29M | 31.65M | 31.18M | 31.50M | 27.80M | 8.31M | 60.66M | 90.59M | 47.29M | 10.03M | 11.10M | 11.74M | 12.96M |
| EBITDA | 229.96M | 174.43M | 106.63M | 130.29M | 61.67M | 64.84M | 88.40M | 101.30M | 68.37M | 50.57M | 62.30M | 31.42M | 25.70M | 10.76M | 32.11M | 25.47M |
| EBITDA Ratio | 21.15% | 15.82% | 11.79% | 11.67% | 12.12% | 9.52% | 15.42% | 20.22% | 26.43% | 11.87% | 10.93% | 5.60% | 4.66% | 1.30% | 3.24% | 2.09% |
| Operating Income | 184.50M | 67.47M | 79.63M | 68.99M | 18.80M | -29.70M | 2.66M | 38.40M | 50.23M | 7.47M | -28.59M | -15.87M | 15.67M | -337.66K | 18.50M | 12.51M |
| Operating Income Ratio | 16.97% | 7.30% | 7.21% | 7.16% | 2.21% | -3.89% | 0.43% | 6.14% | 9.37% | 1.30% | -5.04% | -2.83% | 2.84% | -0.04% | 1.98% | 1.03% |
| Total Other Income/Expenses | 22.32M | -28.51M | -43.17M | -100.08M | -16.17M | -95.46M | -77.73M | -174.00K | -31.81M | -8.81M | -20.93M | -16.26M | -7.32M | 11.16M | -10.22M | -1.01M |
| Income Before Tax | 206.82M | 158.90M | 195.62M | 107.87M | 29.08M | 27.56M | 46.40M | 56.40M | 97.37M | -27.12M | -49.51M | -32.13M | 8.36M | 10.82M | 10.15M | 11.50M |
| Income Before Tax Ratio | 19.02% | 17.20% | 17.70% | 11.19% | 3.43% | 3.61% | 7.50% | 9.02% | 18.17% | -4.72% | -8.73% | -5.73% | 1.52% | 1.31% | 1.09% | 0.94% |
| Income Tax Expense | 39.06M | 33.08M | 54.70M | 35.39M | 10.54M | 17.45M | 18.34M | 31.20M | 28.91M | -13.14M | 2.04M | 11.55M | 3.07M | 1.78M | 2.18M | 7.71M |
| Net Income | 167.77M | 126.32M | 140.92M | 72.47M | 18.53M | 10.12M | 28.07M | 25.20M | 68.46M | -13.98M | -51.55M | -43.68M | 5.29M | 9.04M | 7.97M | 3.79M |
| Net Income Ratio | 15.43% | 13.67% | 12.75% | 7.52% | 2.18% | 1.32% | 4.53% | 4.03% | 12.77% | -2.44% | -9.09% | -7.78% | 0.96% | 1.09% | 0.85% | 0.31% |
| EPS | 7.97 | 5.98 | 6.70 | 3.44 | 0.88 | 0.45 | 1.33 | 1.20 | 3.25 | -0.66 | -2.45 | -2.08 | 0.25 | 0.43 | 0.38 | 0.18 |
| EPS Diluted | 7.97 | 5.98 | 6.70 | 3.44 | 0.88 | 0.45 | 1.33 | 1.20 | 3.25 | -0.66 | -2.45 | -2.08 | 0.25 | 0.43 | 0.38 | 0.18 |
| Weighted Avg Shares Out | 21.04M | 21.04M | 21.04M | 21.04M | 21.04M | 22.48M | 21.04M | 21.04M | 21.04M | 21.18M | 21.04M | 21.00M | 21.04M | 21.04M | 21.04M | 21.04M |
| Weighted Avg Shares Out (Dil) | 21.04M | 21.04M | 21.04M | 21.04M | 21.04M | 22.48M | 21.04M | 21.04M | 21.06M | 21.18M | 21.04M | 21.00M | 21.04M | 21.04M | 21.04M | 21.04M |
Source: https://incomestatements.info
Category: Stock Reports